Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.
Pinto, D.J., Galemmo, R.A., Quan, M.L., Orwat, M.J., Clark, C., Li, R., Wells, B., Woerner, F., Alexander, R.S., Rossi, K.A., Smallwood, A., Wong, P.C., Luettgen, J.M., Rendina, A.R., Knabb, R.M., He, K., Wexler, R.R., Lam, P.Y.(2006) Bioorg.Med.Chem.Lett. 16: 5584-5589
- PubMed: 16963264 
- DOI: 10.1016/j.bmcl.2006.08.027
- PubMed Abstract: 
The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa. The compound 3-[6-(2'-dimethylaminomethyl-biphenyl-4-yl)-7-oxo-3-trifluoro-methyl- ...